Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS -- Ignore unavailable to you. Want to Upgrade?

To: Basildon Bond who wrote (443)	3/25/1999 7:40:00 PM
From: Silicon Mo	Read Replies (1) \| Respond to of 518

I am on CELN's e-mail list and received this tonight. I also got the news at DLJDirect.com. March 25, 1999 Dear Investors: We attached herewith today's Press Release regarding Prostate Cancer. We appreciate your interest in our Company's stock and please feel free to contact us should you have any question. CELSIONTM CORPORATION NEWS RELEASE John Mon Geoffrey Eiten Celsion Corporation OTC Financial Network (410) 290-5390 (888) 399-7541 / (781) 444-6100 www.celsion.com www.otcfn.com/celn FOR IMMEDIATE RELEASE: CELSION ACQUIRES EXCLUSIVE RIGHTS TO MICROWAVE TECHNOLOGY FOR PROSTATE CANCER TREATMENT -- Technology Expected to Enhance the Treatment of Prostate Cancer When Used in Conjunction with Radiation Seed Implants -- Columbia, MD - March 25, 1999: Celsion Corp. (OTC BB: CELN) today announced that it acquired from MMTC, Inc., a Princeton, NJ-based developer of microwave technologies, the exclusive worldwide rights to commercialize MMTC's patented microwave heat and compression technology for prostate cancer treatment. Celsion reported that a prostate cancer treatment system based on the recently licensed technology has been produced. Successful development of the system will allow the Company to enter the $6 billion U.S. prostate cancer treatment market. According to Celsion President and CEO Spencer Volk, "Today's agreement with MMTC expands our growing technology portfolio. We are now pursuing research collaborations to begin the evaluation of our prostate cancer system's safety and efficacy." BREAST CANCER & BPH CLINICALS In addition to its prostate cancer treatment system, Celsion is planning to begin phase one clinicals of its breast cancer treatment system that has Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA). Celsion is also conducting phase one clinicals, which are expected to be completed shortly, for its non-surgical, outpatient treatment of benign prostatic hyperplasia (BPH). Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and BPH using focused heat delivered by patented microwave technology. Clinicals and further development of the Company's treatment systems are being conducted by leading institutions such as the Massachusetts Institute of Technology, Massachusetts General Hospital, Montefiore Medical Center, and Duke University. Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, possible changes in cost of materials, expense items, capital expenditures, capital structure, and other financial items; introduction of new products and possible acquisitions of assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.